Urothelial Carcinoma clinical trials in Michigan

Pembrolizumab and sacituzumab govitecan for advanced bladder cancer

This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.

Using a blood test to guide immunotherapy after bladder/kidney cancer surgery

This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.

Immunotherapy plus a targeted drug for rare genitourinary tumors

This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.

Registry for adults with UTUC treated with Jelmyto

This registry collects information about adults with upper tract urothelial cancer (UTUC) who received Jelmyto after it was approved. It helps doctors understand outcomes and real-world experience with Jelmyto.

Single-use digital scope for kidney cancer surveillance

This trial tests a new, disposable flexible camera (ureteroscope) to safely check for or monitor upper urinary tract cancer in an office setting without putting you to sleep. The goal is to see if patients can tolerate this procedure comfortably while awake.

Adding immunotherapy to radiation for bladder cancer

This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.

Using a light-sensitizing drug to find cancer in the upper urinary tract

This trial tests whether taking a drug called 5-ALA before a scope procedure helps doctors spot cancer cells in the upper urinary tract more clearly. If you are having a scope to check for or treat a tumor in this area, this experimental imaging method might help guide treatment.

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Study of DCC-2812 for advanced genitourinary cancers

This trial tests an experimental pill called DCC-2812 for people with advanced kidney, bladder, or prostate cancer. The goal is to see if it is safe and if it might help shrink tumors or slow the cancer's growth.

New OX40 immunotherapy for advanced solid tumors

This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.

Study of two drugs before surgery for upper tract cancer

This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, given before surgery for upper tract urothelial cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes for patients who are candidates for surgery.

New drug combinations for advanced solid tumors

This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.

Futibatinib and durvalumab before bladder cancer surgery

This trial tests two drugs (futibatinib and durvalumab) given before bladder removal surgery for people with muscle-invasive bladder cancer who cannot take standard cisplatin chemotherapy. The goal is to see if the combination shrinks the tumor and improves outcomes.

Collecting urine to test a new bladder cancer detection method

This study collects urine samples to test UroAmp, a new genetic test that may help detect and monitor bladder cancer. It is for people with bladder cancer or blood in urine who want to help improve cancer detection.

Study of MT-4561 for advanced solid tumors

This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.

Study for HER2-positive bladder cancer after limited treatment

This Phase 2 trial tests disitamab vedotin alone or with pembrolizumab for urothelial (bladder/urinary tract) cancer that has HER2-positive tumors. It aims to shrink tumors and improve outcomes, including for people who have had limited prior treatment or specific prior drug exposures.

AI matches your cancer tests to possible treatment trials

This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.

DBC-664 for adults with advanced solid tumors

This trial tests a new drug called DBC-664 for people with solid tumors that have come back or spread and cannot be removed by surgery. It may be an option if you have tried other treatments or if standard options are limited.

Durvalumab plus chemo before surgery for upper tract cancer

This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.

Study of BL-M07D1 for HER2-positive solid tumors

This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.

Study of AKY-1189 for advanced solid tumors

This trial tests a new radioactive drug, AKY-1189, for people with solid tumors that have spread or cannot be removed. It may help if other treatments have stopped working.

Study of zanidatamab for HER2-positive solid tumors

This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.

Shorter radiation for bladder cancer with chemo

This trial tests if a shorter course of radiation therapy works as well as the usual longer course for people with bladder cancer who are also receiving standard chemotherapy. The goal is to see if shorter treatment can reduce side effects while still being effective.

Study of RNDO-564 alone or with pembrolizumab for bladder cancer

This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.